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Management of relapsed and refractory multiple myeloma:
novel agents, antibodies, immunotherapies and beyond
CS Chim1, SK Kumar2, RZ Orlowski3, G Cook4, PG Richardson5, MA Gertz2, S Giralt6, MV Mateos7, X Leleu8 and KC Anderson5
Despite enormous advances, management of multiple myeloma (MM) remains challenging. Multiple factors impact the decision to
treat or which regimen to use at MM relapse/progression. Recent major randomized controlled trials (RCTs) showed widely varying
progression-free survivals (PFS), ranging from a median of 4 months (MM-003) to 23.6 months (ASPIRE). Based on these RCTs,
next-generation proteasome inhibitors (carﬁlzomib and ixazomib), next-generation immunomodulatory agent (pomalidomide), and
monoclonal antibodies (elotuzumab and daratumumab) were approved for relapsed and refractory MM. Daratumumab, targeting
CD38, has multiple mechanisms of action including modulation of the immunosuppressive bone marrow micro-environment. In
addition to the remarkable single agent activity in refractory MM, daratumumab produced deep responses and superior PFS in MM
when combined with lenalidomide/dexamethasone, or bortezomib/dexamethasone. Other anti-CD38 antibodies, such as
isatuximab and MOR202, are undergoing assessment. Elotuzumab, targeting SLAMF7, yielded superior response rates and PFS
when combined with lenalidomide/dexamethasone. New combinations of these next generation novel agents and/or antibodies
are undergoing clinical trials. Venetoclax, an oral BH3 mimetic inhibiting BCL2, showed single agent activity in MM with t(11;14),
and is being studied in combination with bortezomib/dexamethasone. Selinexor, an Exportin-1 inhibitor, yielded promising results
in quad- or penta-refractory MM including patients resistant to daratumumab. Pembrolizumab, an anti-PD1 check-point inhibitor, is
being tested in combination with lenalidomide/dexamethasone or pomalidomide/dexamethasone. Chimeric antigen receptor-T
cells targeting B-cell maturation antigen have yielded deep responses in RRMM. Finally, salvage autologous stem cell
transplantation (ASCT) remains an important treatment in MM relapsing/progressing after a ﬁrst ASCT. Herein, the clinical trial data
of these agents are summarized, cautious interpretation of RCTs highlighted, and algorithm for salvage treatment of relapse/
refractory MM proposed.
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INTRODUCTION
Despite enormous advances with the advent of proteasome
inhibitors (PI) and immunomodulatory agents (IMiDs), manage-
ment of multiple myeloma (MM) remains challenging, and relapse
of MM and disease progression is common even after achieve-
ment of a complete remission.1 Moreover, relapsed/progressive
MM acquires additional mutation or genetic alterations that
render the disease more resistant, leading to progressively shorter
durations of remission or response to each salvage therapy, and
the ultimate development of relapsed/refractory MM (RRMM).2
FACTORS IMPACTING DECISIONS TO TREAT AND THE CHOICE
OF SALVAGE REGIMENS
While treatment is often indicated at relapse/progression of MM, a
number of factors need to be considered before embarking on
therapy. The ﬁrst question is whether it is a true MM relapse. This
is particularly important with more effective induction regimens,
often followed by autologous stem cell transplantation (ASCT),
rendering a deep response (4very good partial response) in the
majority of transplant-eligible MM patients.3 However, it was well
recognized that patients with a deep response may develop
oligoclonal reconstitution, characterized by the transient presence
of a monoclonal gammopathy of a different isotype (Figure 1) but
occasionally with the same isotype.4–6 While oligoclonal recon-
stitution may result in a measurable M-protein, it is often transient,
lasting for a period of weeks to up to a year.5,7 Therefore,
recognition of oligoclonal reconstitution is important in order not
to over-treat the patients and expose them to unnecessary
toxicity, especially when it may be associated with a good
prognosis.8
Clinically, some relapses occur in the form of symptomatic
disease with the presence of hypercalcemia, renal impairment,
anemia or bone disease (CRAB) or extramedullary disease, either in
the form of plasma cell leukemia or extramedullary plasmacytoma,
and warrant immediate treatment.9 However, in many cases,
relapse/progression may be biochemical only, which is marked by
reappearance or increase in the amount of measurable M-protein
without symptoms. This biochemical relapse, deﬁned as a 25%
increase in M-protein with an absolute increase of 0.5 g/dl,10 does
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not warrant treatment. Moreover, in the case of biochemical
relapse/progression, some progress in an indolent manner, while
others demonstrate an aggressive pattern with rapid doubling of
the M-protein.9 Therefore, based on the rate of rise or the absolute
rise of paraprotein, treatment is recommended if there is a
‘signiﬁcant’ biochemical relapse, which includes any of the
following in two consecutive measurements within 2 months: (1)
doubling of the M-component with an absolute value ⩾ 5 g/l, or
(2) an increase in the absolute levels of serum M-protein by ⩾ 1 g/
dl, or urine M-protein by ⩾ 500 mg/24 h, or involved FLC level by
⩾ 20 mg/dl (plus an abnormal FLC ratio).11,12 Many factors affect
the decision or choice of salvage therapy including age of the
patient (for example, still eligible for a second ASCT?), duration of
response to prior induction or ASCT, side-effects carried over from
prior treatments (for example, peripheral neuropathy), co-morbid
illnesses (caution with the use lenalidomide in renal impairment or
carﬁlzomib in cardiac failure) performance status, or the presence
of high-risk karyotypic aberrations such as del(17p), which would
predict a short response to high-dose chemotherapy in the form
of a second ASCT.13,14 Finally, evidence from clinical trials,
especially those from phase 3 randomized controlled trials (RCTs);
inﬂuence the choice of salvage therapy. Herein, we discuss the
most important clinical trials published in the last 2 years and
some promising ongoing clinical trials.
COMMON FEATURES OF RCTS IN MM
In 2015− 2016, multiple drugs were approved for the treatment of
RRMM including carﬁlzomib, ixazomib, pomalidomide, panobino-
stat, elotuzumab and daratumumab, based on positive results
from high-quality, phase 3 studies.15–22 A common theme in the
phase 3 RCT was that RRMM patients in the intervention arm were
compared with a standard salvage regimen of lenalidomide/
dexamethasone (Rd) or bortezomib/dexamethasone (Vd) in the
majority but not all, hence randomized to ‘X’-Rd/Vd or Rd/Vd,
hence a three-drug versus two-drug design. The primary end-
point was often progression-free survival (PFS), while response
rate (RR) and overall survival (OS) were secondary end-points.
However, some studies also included minimal residual disease
(MRD) as a secondary end-point.15,18,23 Over the last 2 years, a
number of important clinical trials have been published that
reshaped the current landscape of treatment of RRMM (Table 1).
Important published RCTs of next-generation PI include ASPIRE15
which compared carﬁlzomib/lenalidomide/dexamethasone (KRd)
with Rd; and TOURMALINE,16 which compared Ixazomib-Rd with
Rd. MM-003 was an RCT that compared pomalidomide/low dose
dexamethasone with high-dose dexamethasone.17 Important
studies of monoclonal antibodies included daratumumab and
elotuzumab.18,20–23 If one refers to v.3 2017 National Comprehen-
sive Cancer Network (NCCN) guideline for patients with RRMM,
there are a multitude of ‘category 1’ salvage agents/regimens
including bortezomib/dexamethasone, lenalidomide-dexamethasone
elotuzumab-lenalidomide-dexamethasone, ixazomib-lenalido-
mide-dexamethasone, carﬁlzomib-lenalidomide-dexamethasone,
bortezomib/panobinostat/dexamethasone, pomalidomide/dexa-
methasone, daratumumab-lenalidomide-dexamethasone and
bortezomib-lenalidomide-dexamethasone24 (Figure 2).
CAUTION IN INTERPRETATION OF CLINICAL TRIAL DATA
The PFS data from these studies are widely different. For instance,
median PFS was 26.3 months in the KRd arm of the ASPIRE study
but only four months in the intervention arm of MM-003 using
pomalidomide/dexamethasone.15,17 While no two studies are
directly comparable, the huge difference in PFS of these two
studies could at least be partially accounted for by the patient
populations in the trials. For instance, in MM-003, 95% of patients
had ⩾ 3 lines of therapy, 82% were refractory to their last regimen,
and 75% were double refractory to bortezomib and lenalidomide
(Table 1). By contrast, in ASPIRE the median number of prior lines
of therapy was two, and none were double refractory to
bortezomib and lenalidomide since the control arm was Rd.
Therefore, one has to be cautious in the comparison of results
across clinical trials. Most RCTs (including ASPIRE, TOURMALINE,
CASTOR, POLLUX and ELOQUENT-2) were conducted at an earlier
state of relapse,15–18,20,23 when the median number of prior lines
of therapy was limited to one or two only, and few patients were
refractory to their last regimen or double refractory to both
bortezomib and lenalidomide (Table 1). By contrast, in MM-003,
GEN501 and SIRIUS, patients had a median of 4–5 prior
treatments, with 480% refractory to their last regimen and three
quarters refractory to both bortezomib and lenalidomide. There-
fore, meaningful comparison could only be made among trials
comprising similar trial design, patient populations and similar
control arms.25
MAJOR CLINICAL TRIALS OF NEXT-GENERATION PIS
Randomized controlled trials including ASPIRE and TOURMALINE
were published in 2015 and 2016, demonstrating the superiority
of the second-generation PIs (carﬁlzomib in ASPIRE and ixazomib
in TOURMALINE) in combination with lenalidomide/dexametha-
sone [Rd] when compared to Rd.15,16
Carﬁlzomib is an intravenous PI carrying an epoxyketone
moiety, and functions as an irreversible inhibitor of the β5
chymotryptic subunit of the 20S proteasome. Ixazomib is an oral
boronate PI with reversible inhibition of the proteasome. In
contrast, bortezomib is a boronate PI with slowly reversible
inhibition of the β5 subunit of the proteasome. In ASPIRE, RRMM
patients were randomized to receive carﬁlzomib-Rd [KRd] or Rd
only (Figure 2). Much higher response rates and a superior PFS
were observed in the KRd arm compared with Rd (PFS: 26.3 versus
17.6 months, Po0.0001) In contrast to bortezomib, carﬁlzomib led
to much less peripheral neuropathy but a higher rate of
cardiopulmonary complications. Moreover, tumor lysis syndrome
has occurred and hence a ramped-up schedule of carﬁlzomib has
been adopted (20 mg/m2/d on D1/2, followed by 27 mg/m2/d on
D8/9, D15/16 of cycle one and thereafter). Moreover, in an
updated analysis, (KRd) has been shown to confer an OS beneﬁt
by reducing the risk of death by 21% over Rd alone, hence an
almost 8-month survival prolongation (median OS: 48.3 months
versus 40.4 months, HR = 0.79) (https://www.amgen.com/media/
news-releases/2017/07/second-phase-3-study-shows-kyprolis-car
ﬁlzomib-regimen-signiﬁcantly-improves-overall-survival-in-
patients-with-relapsed-multiple-myeloma/).
Recently, a head-to-head comparison of carﬁlzomib with
bortezomib has been conducted in the ENDEAVOR trial, in which
patients with RRMM were randomized to receive carﬁlzomib/
dexamethasone (Kd)(N= 464) or bortezomib/dexamethasone (Vd)
Figure 1. Oligoclonal reconstitution (OCR) illustrated by the change
of monoclonal IgAL at diagnosis (Dx) to OCR of IgGk+IgGL+IgMk
during complete remission.
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(N= 465)19 (Figure 2). In this study, patients with prior exposure
but who were not refractory to bortezomib or carﬁlzomib were
eligible. Patients receiving Kd had a higher response rate (RR)/
⩾ complete remission (CR)/very good partial response (VGPR) rates
(RR/⩾CR/⩾ VGPR rates: 77%/13%/54% versus 63%/29%/6%,
Po0.0001) and superior PFS than those receiving Vd (median
PFS: 18.7 months versus 9.4 months, HR: 0.53, Po0.0001). An
updated report of ENDEAVOR study showed that Kd provided
7.6 months median OS beneﬁt (median OS: 47.6 months versus
40.0 months Vd; HR 0.791; P= 0.010).26 If the subset of patients
with prior exposure to bortezomib is excluded and only
bortezomib-naïve RRMM patients are analyzed, the RR and PFS
of the Kd arm remained superior to that of the Vd arm.27
Therefore, carﬁlzomib appears to be a more potent PI than
bortezomib in this setting.
In TOURMALINE,16 RRMM patients were randomized to receive
ixazomib (Ixa)-Rd (N= 360) or Rd only (N= 362). Compared to the
Rd control, the Ixa-Rd arm led to superior response rates (RR/
⩾CR/⩾VGPR: 78%/14%/48% versus 72%/7%/39%) and PFS
(20.6 months versus 14.7 months, HR: 0.74, P= 0.01) (Figure 2).
Moreover, in patients with high-risk cytogenetics, Ixa-Rd resulted
in a superior PFS (21.4 months) than placebo-Rd (9.7 months, HR:
0.543), comparable to PFS of 20.6 months in standard-risk treated
by Ixa-Rd.28 Therefore, the adverse impact of high-risk cytoge-
netics has been abolished by Ixa-Rd.
MAJOR CLINICAL TRIALS OF NEXT-GENERATION IMID
Pomalidomide, a third-generation IMiD more potent than
lenalidomide, has been shown to yield superior RR and PFS
compared to high-dose dexamethasone in the MM-003 study.17 In
MM-003, ‘refractory’ MM patients were randomized to receive oral
pomalidomide (4 mg/d D1-D21) and low dose dexamethasone
(40 mg weekly), Pd, at 4-weekly intervals versus high-dose
dexamethasone (40 mg/d D1-4, D9-12, D17-20). RR/⩾CR/⩾ VGPR
rates were 31%/1%/6% in the Pd arm and 10%/0%/o1% in the
control arm, and median PFS was 4.0 months and 1.9 months (HR:
0.48; Po0.0001). Recently, a randomized phase 2 study reported a
higher response rate (65% versus 39%, P= 0.035) and superior
median PFS (9.5 months versus 4.4 months) in patients receiving
pomalidomide, cyclophosphamide, dexamethasone (PCd) than
Pd.29 Moreover, a phase 3 study (MM-007) comparing the efﬁcacy
and safety of pomalidomide-bortezomib-dexamethasone (Pom-
Vd) with bortezomib-dexamethasone (Vd) is ongoing in RRMM.30
MAJOR CLINICAL TRIALS OF HDAC INHIBITOR
In MM, resistance to bortezomib has been attributed at least in
part to activation of the histone deacetylase (HDAC) 6-dependent
aggresome pathway that leads to catabolism of excessive
unfolded proteins, thereby precluding induction of cellular
apoptosis by cellular stress inherent with excessive unfolded
Figure 2. An array of salvage regimens for RRMM comprising proteasome inhibitor (PI), immunomodulatory agents (IMiD), anti-CD38
(daratumumab [Dara]) or anti-SLAMF7 (elotuzumab [Elo]) monoclonal antibodies, BCL2 inhibitor (BCL2i), exportin-1 inhibitor (XPO1-i), anti-
PD1 check-point inhibitors or CAR-T cells. PI (bortezomib [V], carﬁlzomib [K] and ixazomib [Ixa]) and dexamethasone [Dex] induces intrinsic/
mitochondrial apoptosis (via activation of caspase 9 through formation of the apoptosome) while IMiD (lenalidomide [R] and pomalidomide
[P]) extrinsic apoptosis via activation of caspase 8. Low-dose dexamethasone (d) can be combined with either IMiD (Rd or Pd), or PI (Vd or Kd)
to yield effective doublets, or both IMiD and PI to generate even more potent triplets including VRd, VPd, KRd, KPd and Ixa-Rd. Monoclonal
antibody combinations targeting CD38 (Dara-Vd, Dara-Rd or Dara-Pd) or SLAMF7 (Elo-Rd) are effective salvage regimens. Venetoclax (VEN), or
in combination with Vd, induces mitochondrial apoptosis. Selinexor (SEL)is an exportin-1 inhibitor, resulting in nuclear retention of tumor
suppressor proteins (TSP). Check-point inhibitors (anti-PD1) such as pembrolizumab (Pem) or its combinations (Pem-Rd, Pem-Pd) unleash
endogenous myeloma-speciﬁc cytotoxic T-cells (MM CTL) to induce cell-mediated myeloma cytotoxicity. Adoptive cell therapy with
engineered autologous BCMA-speciﬁc CAR-T cells leads cell-mediated cytotoxicity.
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protein upon proteasome inhibition.31–33 Panobinostat is an oral
pan-HDAC inhibitor that produces synergistic antimyeloma effects
when combined with bortezomib and dexamethasone. A rando-
mized, placebo-controlled, double-blind phase 3 trial comparing
panobinostat, bortezomib and dexamethasone with placebo,
bortezomib and dexamethasone has been conducted in patients
with RRMM,34 which yielded a median PFS of 11.99 months in the
panobinostat combination arm and 8.08 months in the placebo
control arm (HR: 0.63, Po0.0001). Response rate was not different
between the arms but CR or near CR rates were higher in the
panobinostat combination (27.6% versus 15.7%, Po0.0006).
However, grade 3/4 thrombocytopenia (67%), diarrhea (26%)
and asthenia (24%) occurred more frequently in the panobinostat
arm. A selective HDAC 6 inhibitor ricolinostat has been studied in
combination with bortezomib and dexamethasone in RRMM.35
Compared to panobinostat, patients receiving ricolinostat at
160/240 mg daily together with bortezomib/dexamethasone
(N= 20) had comparable RR/VGPR rates (37%/11%), but much
less grade 3/4 thrombocytopenia (20%), asthenia (5%) and
diarrhea (5%).
MAJOR CLINICAL TRIALS OF MONOCLONAL ANTIBODIES
Promising results were seen in studies of daratumumab, either as
a single agent,21,22 or in combination with bortezomib/dexa-
methasone (DVd) or lenalidomide/dexamethasone (DRd).18,23
Daratumumab is a fully humanized IgG1 antibody targeting
CD38, a transmembrane glycoprotein uniformly expressed at high
levels in MM plasma cells, but at low levels in normal myeloid and
lymphoid cells. Daratumumab has a multiple mechanisms of
action.36 First, binding of daratumumab to CD38 of myeloma
plasma cells directly induces apoptosis. Moreover, myeloma cell
death is also mediated by complement-dependent cytotoxicity,
antibody-dependent cell-mediated cytotoxicity (ADCC), and
antibody-dependent cellular phagocytosis. Besides, daratumumab
also modulates the immunosuppressive bone marrow microenvir-
onment favorably by suppressing production of immunosuppres-
sive molecules such as adenosine by inhibition of CD38 enzymatic
activity on myeloma plasma cells. On the other hand, CD38 is also
expressed on the immunosuppressive regulatory T-cells (Treg) and
myeloid-derived suppressor cells which are hence also targeted
and inhibited by daratumumab, thereby relieving repression of
the myeloma-speciﬁc cytotoxic T cells in the bone marrow
microenvironment.36
Clinically, signiﬁcant single agent activity of daratumumab in
myeloma has been demonstrated in two studies GEN501 (a phase
1–2 study) and SIRIUS.21,22 In the phase 2 study, SIRIUS, patients
with refractory MM with a median of ﬁve prior lines of therapy,
97% refractory to their last regimen and 85% refractory to both
bortezomib and lenalidomide, were enrolled.21 A total of 106
patients received 16 mg/kg daratumumab (weekly × 8, then 2-
weekly × 8, then 4-weekly thereafter). In this highly refractory
cohort of MM, RR/⩾CR/⩾ VGPR rate were 29.2%/2.8%/9.4%, with
a median PFS of 3.7 months and OS of 17.5 months, demonstrat-
ing signiﬁcant single agent activity of daratumumab in MM. The
median time to ﬁrst response was only one month, indicating a
rapid onset of action. In the phase 1/2 GEN501 study,22 in which
80% of patients were refractory to their last regimen and 64% had
MM double refractory to both bortezomib and lenalidomide), no
maximum tolerated dose was identiﬁed in the dose-escalation
phase. Moreover, in the dose-expansion phase, 42 patients with
advanced MM and a median of four prior lines of therapy received
intravenous once weekly daratumumab (16 mg/kg weekly for 8
doses over 2 months, 2-weekly for 8 doses over 4 months and
then monthly thereafter until disease progression), The RR/⩾CR/
⩾VGPR rates were 36%/6.7%/6.7% with a median PFS of
5.6 months. Finally, in a combined analysis of all MM patients
receiving daratumumab 16 mg/kg (weekly × 8, 2-weekly × 8, and
then 4 weekly thereafter until disease progression) in both
GEN501 (N= 42) and SIRIUS (N= 106) clinical trials, the RR/⩾CR/
⩾VGPR rates were 31%/4.7%/8.8% and median PFS was 4 months
and OS 20.1 months.37 Interestingly, while median PFS was only
4 months, it translated into a prolonged median survival of 20
months.37
Building on these promising data from single agent daratumu-
mab, subsequent trials have compared bortezomib/dexametha-
sone (Dara-Vd) or lenalidomide/dexamethasone (Dara-Rd) with or
without daratumumab in phase 3 RCTs18,23 (Figure 2). In the
CASTOR study,18 patients with RRMM were randomized to receive
Dara-Vd (N= 251) or Vd (N= 247). In the Dara-Vd arm, patients
received daratumumab (weekly × 9, then every 3-weeks × 15, and
then every 4-weeks thereafter until disease progression) in
addition to eight 3-weekly cycles of bortezomib/dexamethasone
(bortezomib 1.3 mg/m2 subcutaneously on D1,4,8,11 Q3W and
dexamethasone 20 mg/d on D1/2, 4/5, 8/9, 11/12). Patients in the
control Vd arm received eight cycles of Vd as described above. The
CASTOR trial reported encouraging RR/⩾CR/⩾VGPR rates of 83%/
19%/59% and the median PFS was not reached in the Dara-Vd
arm compared with a median PFS of 7.2 months in the Vd control
(HR: 0.39; Po0.0001). In the POLLUX study,23 patients with RRMM
were randomized to receive Dara-Rd (N= 286) or Rd only (N= 283).
In the Dara-Rd arm, patients received daratumumab at 16 mg/kg
(weekly × 8, 2-weekly × 8, and 4-weekly thereafter) in addition to
the regular 4-weekly cycles of Rd (lenalidomide 25 mg/d D1-D21,
dexamethasone 40 mg weekly) until disease progression. The
study yielded very promising results with RR/⩾CR/⩾VGPR rates
of 93%/43%/78%, and an 18-month PFS of 78% (median not
reached) compared to the 18-month PFS of 52% and median PFS
of 18.4 months in the Rd control arm (HR: 0.037; Po0.0001).
While two RCTs should not be directly compared, it would
appear that responses in the Dara-Rd arm of POLLUX (RR/⩾CR/
⩾VGPR rates: 93%/43%/78%) were higher than that in the Dara-Vd
arm of CASTOR (RR/⩾CR/⩾VGPR rates: 83%/19%/59%). Moreover,
the 12-month PFS of POLLUX (83%) was higher than CASTOR
(60.7%). In these two studies, there was no major difference in
patient population in terms of the status of disease at enrolment
(30% were refractory to their last treatment in Dara-Vd and 28% in
Dara-Rd) and cytogenetic proﬁles with high-risk cytogenetics (22%
of Dara-Vd and 19% of Dara-Rd).18,23 However, per protocol, a total
of 16 doses of daratumumab were used in Dara-Rd during
induction, compared to a total of 14 doses in Dara-Vd. Moreover,
in the maintenance phase, continual Rd in addition to monthly
daratumumab was used until disease progression in DRd. In
contrast, only single agent daratumumab was used after cycle 8 of
Dara-Vd in CASTOR and no maintenance of bortezomib was given.
Therefore, differences in dose intensity, especially with the use of
additional Rd during maintenance in the Dara-Rd arm, may
account, at least in part, for the difference in RR and PFS in Dara-
Rd of POLLUX and Dara-Vd of CASTOR.
In an updated analysis of POLLUX and CASTOR, objective
response rate and PFS were reported according to the cytogenetic
risk status as detected by NGS, in which high-risk cytogenetic
aberrations were those with t(4;14), t(14;16) or del(17p), and
standard-risk those without.38 Addition of daratumumab to either
lenalidomide/dexamethasone (Rd) or bortezomib/dexamethasone
(Vd) yielded a superior PFS and a higher rate of deep responses
(⩾CR or ⩾VGPR) in both high-risk and standard-risk subgroups
than Rd/Vd only. In particular, the adverse impact of high-risk
cytogenetics on PFS was mitigated by addition of daratumumab
to either Rd or Vd. Moreover, at a sensitivity of one in 105, addition
of daratumumab to Rd yielded a higher rate MRD negativity in
both high-risk and standard-risk cytogenetic subgroups (HR
subgroup: Dara-Rd 18% versus Rd 0%; P= 0.0027; SR subgroup:
Dara-Rd 30% versus Rd 10%; P= 0.0001). Similarly, addition of
daratumumab to Vd resulted in more frequent MRD negativity in
both high-risk and standard-risk cytogenetic subgroups (high-risk
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subgroup: Dara-Rd 14% versus Rd 0%; P= 0.0018; standard-risk
subgroup: Dara-Rd 12% versus Rd 2%; P= 0.0011). Therefore,
addition of daratumumab to Rd or Vd improved treatment
outcomes regardless of cytogenetic risk status in RRMM.38
Besides daratumumab, another anti-CD38 antibody isatuximab
(also called SAR650984), a humanized IgG1 monoclonal antibody,
has been studied in advanced MM. In an open-label, single-arm
study, patients treated with isatuximab at ⩾10 mg/kg (n= 74) had
a median PFS of 3.65 months and a median OS of 18.63 months
(95% CI, 15.7—not reached). The objective response rate was
24.3%, including those with high-risk cytogenetics.39 Another anti-
CD38 antibody MOR202, a human combinatorial antibody library-
derived human IgG1 CD38 monoclonal antibody, induces
antibody-dependent cell-mediated cytotoxicity and antibody-
dependent cellular phagocytosis, but not complement-
dependent cytotoxicity, which is suspected to be a major cause
of infusion-related reactions seen with other anti-CD38 antibodies.
MOR202 is currently undergoing clinical trials in combination with
lenalidomide or pomalidomide, and preliminary results revealed
excellent tolerability with infusion-related reactions in only 10% of
patients, all ⩽grade 2.40 This compared favorably with the much
higher rates of infusion-related reaction, though mostly grade 1/2
and limited to the ﬁrst infusion, occurring in 43–71% of patients
treated with daratumumab monotherapy and 43% of patients
receiving isatuximab monotherapy.41
Elotuzumab is a humanized IgG1 monoclonal antibody target-
ing signaling lymphocytic activation molecule family member 7
(SLAMF7), a member of the SLAM family which belongs to the
immunoglobulin receptor superfamily. SLAMF7 is densely
expressed on myeloma plasma cells and natural killer cells.42 In
contrast to daratumumab that demonstrates signiﬁcant single
agent activity in MM, binding of elotuzumab to SLAMF7 of
myeloma plasma cells does not induce tumor cytotoxicity.42 On
the other hand, binding of elotuzumab to NK cells leads to
activation of NK cells, resulting in antibody-dependent cell-
mediated cytotoxicity of elotuzumab-bound myeloma plasma
cells. In the phase 3 study informed by preclinical studies,43
ELOQUENT-2 in which RRMM patients were randomized to receive
intravenous elotuzumab (10 mg/kg weekly × 8, then every 2 weeks
thereafter) or placebo with Rd (lenalidomide 25 mg/d D1-D21 and
dexamethasone 40 mg weekly) at 4-weekly intervals, RR/⩾CR/
⩾VGPR rates were 79%/4%/33% with a superior median PFS of
19.4 months in the Elo-Rd arm and 14.9 months in the Rd arm (HR:
0.7; Po0.001)20 (Figure 2). With an extended follow-up at 4 years,
there was a sustained 29% reduction of progression/death (HR:
0.71; 95% CI: 0.59–0.86) in addition to a trend of OS beneﬁt (4-year
OS: 50% versus 43%; HR: 0.78; 95% CI: 0.63–0.96) in ELo-Rd
compared with Rd.44 As the survival beneﬁt of both PFS and OS
were apparent early in the trial, and persisted thereafter, this is the
ﬁrst immune-oncology study supporting a sustained survival
beneﬁt associated with addition of elotuzumab to Rd.
PHASE1/2 CLINICAL TRIALS ARISING FROM THE PUBLISHED
RCTS
Apart from these RCTs, other permutations of the newer genera-
tion novel PI and IMiDs have been studied. In lenalidomide-
refractory MM patients, bortezomib has been combined with
pomalidomide/dexamethasone (VPd), and carﬁlzomib with poma-
lidomide/dexamethasone (KPd) (Figure 2). Lacy et al. reported
results for the use of VPd (N= 47) to treat patients with
lenalidomide-refractory MM and observed impressive RR/⩾CR/
⩾VGPR rates (85%/19%/44.7%) and a median PFS of 10.7
months.45 In a phase 1 study, KPD showed RR/⩾CR/⩾VGPR rates
of 50%/0%/16%.46 Most recently, a phase 1/2 study of KPd
(N= 64), using twice weekly carﬁlzomib at 27 mg/m2 in combina-
tion with pomaldomide and dexamethasone, yielded a promising
RR/⩾CR/⩾VGPR rates (84%/19%/52%) and median PFS of
16.8 months and 2-year OS of 77%.47
Daratumumab has also been studied in combination with
pomalidomide/dexamethasone (Dara-Pd)48,49 (Figure 2). Dara-Pd
was studied in 103 advanced RRMM, who had a median of four
prior lines of therapy, and were refractory to their last treatment.50
Eighty-nine percent of patients were refractory to lenalidomide,
71% were refractory to bortezomib, and 64% of patients to both
bortezomib and lenalidomide. These patients received daratumu-
mab at 16 mg/kg at the recommended dosing schedule, in
addition to pomalidomide (4 mg daily for 21 days) and
dexamethasone (40 mg weekly). The primary end-point was
safety, and secondary end-points were response rates and MRD
negativity by NGS. Results showed that the safety proﬁle was
similar to pomalidomide/dexamethasone except the infusion
reactions associated with daratumumab. Moreover, serious
adverse reactions (grade 3/4) reported in⩾ 5% patients included
pneumonia (7%). The overall response rate in the study was 60%
(⩾CR/VGPR/PR were 17%/25%/18%), with ⩾VGPR in 42% of
patients. The RR was 58% in those double refractory patients. The
median time to response was 1 month (range = 0.9–2.8 months).
The median PFS and OS were 8.8 months and 17.5 months,
respectively. Response rate was 60%. In patients with ⩾CR, 29%
achieved MRD negativity at a threshold of 10−5. Based on this
study, Dara-Pd was approved by the FDA in June 2017.
AGENTS WITH NOVEL MECHANISM OF ACTION OTHER THAN
PIS, IMIDS OR ANTIBODIES
Apart from these next-generation PIs or IMiDs, drugs with novel
mechanism of action are also being studied in RRMM. Venetoclax
(ABT-199) is an oral BH3 mimetic small molecule inhibiting B-cell
CLL/lymphoma (BCL)-2, an anti-apoptotic protein overexpressed
especially in the t(11;14) MM subtype. Based upon the activity of
venetoclax (VEN) in chronic lymphocytic leukemia (CLL), single
agent venetoclax has been studied in patients with advanced
RRMM in a phase 1 study at dose levels ranging from 300 mg/d to
1200 mg/d (N= 66)51 (Figure 2). The median number of prior lines
of therapy was ﬁve, 79% of patients were refractory to the last
regimen, and 61% double refractory to both bortezomib and
lenalidomide. The study yielded an overall RR/⩾CR/⩾ VGPR of
21%/7%/15%, with much higher responses (RR/⩾CR/⩾VGPR of
40%/14%/27%) and superior PFS in patients with t(11;14) than
those without. A phase 1b study of Venetoclax in combination
with bortezomib and dexamethasone (VEN-Vd) is ongoing52
(Figure 2).
Selinexor is the ﬁrst drug in a new class of agents known as
selective inhibitors of nuclear export.53 Selinexor is an inhibitor of
exportin-1 (XPO-1), a nuclear exporter of the majority of tumor
suppressor proteins, the glucocorticoid receptor, and oncoprotein
mRNAs.54 As a result, selinexor induces nuclear retention and
hence activation of tumor suppressors and glucocorticoid
receptors, in addition to suppression of translation and expression
of oncoproteins such as MYC and BCL-2. In combination with low-
dose dexamethasone, selinexor (SEL) has been studied in quad-
refractory (refractory to bortezomib, carﬁlzomib, lenalidomide and
pomalidomide) or penta-refractory MM, additionally refractory to
a CD38-targeting monoclonal antibody (daratumumab or isatux-
imab) (Figure 2). In this refractory cohort of MM, RR/⩾CR/⩾ VGPR
was 21%/0%/5%, with a median PFS and OS of 2.3 months and
5.5 months respectively. Interestingly, there was a higher RR in
those with high-risk cytogenetics (RR: 35%) than standard-risk
(18%).55
IMMUNOTHERAPY IN MM
In addition to these small molecules and therapeutic monoclonal
antibodies, antibodies against immune check-points are
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undergoing clinical trials in RRMM. Normally, tumor-speciﬁc T-cell
activation involves multiple steps, including priming and activa-
tion that occurs in the regional lymph node where the central
check-point is localized, followed by tumor-speciﬁc cytotoxicity at
the tumor site, that is, the peripheral check-point.56 Ipilimumab (a
cytotoxic T-lymphocyte-associated protein (CTLA)-4 inhibitor) and
pembrolizumab (anti- programmed cell death (PD) 1 inhibitor) are
check-point inhibitors targeting the central and peripheral check-
points respectively.57,58 Pembrolizumab, an anti-PD1 antibody, is
undergoing clinical trials in patients with RRMM in combination
with either lenalidomide/dexamethasone (Pem-Rd) or pomalido-
mide/dexamethasone (Pem-Pd)59,60 (Figure 2). Moreover, chimeric
antigen receptor T-cells therapies targeting B-cell maturation
antigen expressed mainly in plasma cells, or targeting CD19
postulated to be expressed on myeloma stem/progenitor cells,
appear promising and have produced deep responses in
refractory MM.61,62 Promising data from a study of B-cell
maturation antigen-targeting CAR-T cell in 19 RRMM patients
has been recently presented in ASCO63 (Figure 2). The median
number of infused cells was 4.7 × 106/ kg. The median follow-up
times was 208 (range: 62–321) days. Seven were monitored for
46 months, of which six achieved MRD-negativity in addition to
serological CR. Another 12 patients with a follow-up of
o6 months achieved near CR by the modiﬁed EBMT criteria.
Therefore, the overall response rate was 100% with 18 (95%)
achieving ⩾near CR. Acute but manageable cytokine release
syndrome was observed in 14 (74%) patients (grade 1 in 9, grade 2
in 2, and one each of grade 3 and grade 4) patient who received
treatment. No relapse was observed with a median follow-up of
6 months. Therefore, B-cell maturation antigen-targeting CAR-
T cells appear a promising modality of treatment.
ROLE OF SALVAGE ASCT
In patients who relapsed after a prior ASCT, salvage ASCT has been
shown to be an effective consolidation after reinduction therapy
in multiple retrospective studies,64,65 which showed that the most
important factor predicting PFS after salvage ASCT was the
duration of remission from the ﬁrst ASCT. In particular, patients
with a PFS of ⩾ 18 months after initial ASCT are most likely to
beneﬁt from a salvage autotransplant. However, patients with a
o18-month duration of response after initial ASCT should not be
considered for a second autograft in the relapsed setting because
this group will probably only experience ASCT-related toxicity
without substantial clinical beneﬁt.65 In the era of novel agents,
the only RCT to demonstrate the role of salvage ASCT in myeloma
patients at ﬁrst relapse/progression at least 12 months after prior
ASCT was the UK Myeloma X study.66,67 In this study, relapsing
MM patients who achieved at least stable disease after PAD re-
induction (bortezomib/ doxorubicin/dexamethasone) were rando-
mized to receive salvage ASCT (N= 89) or weekly oral cyclopho-
sphamide (N= 85) as consolidation, which showed a superior time
to disease progression (19 months versus 11 months, HR: 0.45;
Po0.0001), and recently OS (67 months versus 52 months, HR:
0.56; P= 0.022) in those receiving salvage ASCT compared with
oral cyclophosphamide consolidation.66 Given that only 174 of
297 enrolled patients were randomized, a relatively large number
of patients did not get randomized. Insufﬁcient stem cell yield was
the main reason that patients were not included in the
randomization, illustrating the importance of mobilizing sufﬁcient
stem cells for at least two ASCTs during the ﬁrst stem cell
harvest.65,66 Therefore, salvage ASCT remains a standard con-
solidation after re-induction in MM patients relapsing/progressing
after ﬁrst ASCT.65–67 This is particularly important in many
countries where patients do not have access to novel agents.
ROLE OF SALVAGE ALLOGENEIC HCT
Salvage allogeneic HCT in MM, in the form of reduced intensity
conditioning (RIC) or non-myeloablative allogeneic SCT (NST), is
performed, particularly in younger patients with either multiple
relapses or short initial remission after ASCT. However, the data
are conﬂicting. For instance, large retrospective registry analysis
suggested no beneﬁt of a salvage allogeneic HCT when compared
to a second autotransplant.68 In contrast, when HLA typing was
performed after relapse from a prior ASCT such that patients with
donor (donor group) received RIC/NST allo-SCT while those
without donors (no donor group) received a second ASCT, De
Lavallade et al. reported a higher PFS but not OS in the ‘donor’
than ‘no donor’ group.69 Similarly, when MM relapses were treated
with novel agent-based induction, Patriarca et al. reported a
signiﬁcant beneﬁt in 2-year PFS for patient with a donor than for
those without (42 versus 18%) (Po0.0001) with similar 2-year OS
of 54% and 53% respectively in patients relapsing after an initial
autograft.70 Therefore, RIC/NST allo-SCT may warrant further study,
particularly in those relapsing within 12 months from prior ASCT,
which remains an unmet medical need.64,65
PROPOSED TREATMENT ALGORITHM FOR MANAGEMENT OF
RRMM
Relapses may be classiﬁed into ‘initial’ (drug-sensitive), ‘inter-
mediate’ or ‘advanced’ (drug-refractory disease) relapses by the
number of prior lines of therapy or refractoriness to PI and/or IMiD,
not by the time from diagnosis to relapse (Figure 3).
Upon relapse, one may use drugs that are naïve to the patient,
drugs of a different class, a more potent version of the same class,
or repeat the same regimen. For instance, in patients relapsing
from Rd, one may consider PI-based regimens (including
bortezomib-, carﬁlzomib- or ixazomib-based regimens),
antibody-based or pomalidomide combinations, preferably in
the form of a triplet. Finally, the original induction regimen can be
repeated in case there is a sufﬁciently long duration of response,
for example ⩾ 2 years.71
Despite that there is no head-to-head comparison among these
novel agents, information about efﬁcacy of the respective
regimens may be inferred from the RCTs if the study design,
end-points and control arms are comparable.25 For instance,
multiple RCTs included patients relapsing with 1− 3 prior lines of
therapy, compared ‘X’-Rd with Rd as control, using PFS as primary
end-point with both the intervention and control arms being
continued till disease progression or intolerable side-effects. With
this framework, there were four clinical trials using Rd as control
including Aspire (KRd versus Rd, HR: 0.69), Tourmaline MM1 (Ixa-
Rd versus Rd, HR: 0.74), Eloquent-2 (Elo-Rd versus Rd, HR: 0.70) and
Pollux (Dara-Rd versus Rd, HR: 0.37), among which the HR of Pollux
was lowest (Table 1). Therefore, Dara-Rd is likely the most potent
regimen among these viable salvage regimens at relapse.
Based on these considerations, a treatment algorithm is
proposed for management of relapses (Figure 3). The regimens
are recommended based on efﬁcacy (by HR in the respective RCT),
prior regimen used, sensitivity to prior regimens (bort- or len-),
and data from phase 3 studies, or at least phase 2 studies. A triplet
is preferred whenever possible. Moreover, while V- or R-refractory
cases mandate use of alternative agents, alternative agents are
preferred but not mandatory in V-/R-exposed but sensitive
patients. In V-refractory patients, KRd or Elo-Rd can be considered
but not Ixa-Rd as V-refractory patients were excluded in Tourma-
line MM1. Finally, while novel agent triplets are generally
preferred, to accommodate affordability in less afﬂuent countries,
less expensive regimens (blue font) in the form of triplet (PCd
instead of KPd) or (Kd or Vd (Aspire) instead of KRd in case of
relapse from, for example, VTD) are also included.
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In ‘Initial’ relapse (Figure 3), in which patients had prior
bortezomib-based induction regimens including VTd, VCd, VMP
or VTP, if they are bortezomib-refractory, the ﬁrst choice of salvage
is Dara-Rd (red font, Figure 3) because of highest efﬁcacy based on
HR. KRd and Elo-Rd but not Ixa-Rd can be considered viable
triplets as 15− 22% V-refractory patients had been enrolled in the
respective RCTs. However, Kd cannot be recommended for
V-refractory relapses, as V-refractory patients had been excluded
in the Endeavor study. In resource-restricted countries, doublet
such as Rd is feasible (blue font, Figure 3). On the other hand, if
patients are only bortezomib-exposed but not refractory, Dara-Rd
and Dara-Vd (red font, Figure 3) are preferred based on their low
HRs (Table 1), followed by other PI-based triplets (KRd, Ixa-Rd, Elo-
Rd or even VRd), or less expensive doublet (Kd, Rd) (blue font,
Figure 3). Moreover, one may consider to repeat the original
regimen if the duration of response is ⩾ 2 years.71 In those who
relapse from Rd induction (Figure 3), if they are R-refractory (for
example, relapse during Rd treatment), antibody-based regimen
(Dara-Vd), pomalidomide combinations (PCd, VPd, Pd), second-
generation PI-combinations (KPd, Kd) or V-based regimens (VCd,
Vd) are viable options. Moreover, less expensive options include
PCd, VCd, Pd, Vd or Kd (blue font, Figure 3) By contrast, in those R-
sensitive relapse, Dara-Rd and Dara-Vd are the most potent
options, followed by KRd, Ixa-Rd, VRd, Elo-Rd, or pomalidomide
combinations (PCd, KPd, VPd), or less expensive regimens such as
VCd, Vd or Kd (blue font, Figure 3). For patients who relapse while
on VRd (Figure 3), they are double V- and R-refractory, hence
managed as ‘intermediate’ relapse. However, if they relapse 2
years after VRd induction, they remain V- and R-sensitive; hence
both V- and R-containing regimens will remain viable options.
Therefore, Dara-Rd and Dara-Vd are ﬁrst choices, followed by KRd,
Ixa-Rd, Elo-Rd, in addition to pomalidomide-containing regimens
Figure 3. Proposed algorithm for the treatment of ‘initial’, ‘intermediate’ or ‘advanced’ myeloma relapses. Those with ‘initial’ relapse may have
been treated with bortezomib (V)-based, lenalidomide (R)-based, or VR-based induction regimens. In ‘initial’ relapse, in which patients had
prior bortezomib-based induction regimens including VTd, VCd, VMP or VTP, if they are bortezomib-refractory, the ﬁrst choice of salvage is
Dara-Rd (red font), followed by KRd. In resource-restricted countries, doublets such as Rd is feasible (blue font). On the other hand, if patients
are only bortezomib-exposed but not resistant, Dara-Rd and Dara-Vd (red font) are the most potent options, followed by other PI-based
triplets (KRd, Ixa-Rd or VRd), or less expensive doublet (Kd, Rd) (blue font). Moreover, one may repeat the original regimen if the duration of
response is ⩾ 2 years. In those who relapse from Rd induction, if they are R-refractory, pomalidomide combinations (PCd, VPd, Pd), second-
generation PI-combinations (KPd, Kd) or V-based regimens (Dara-Vd, VCd, Vd) are viable options. By contrast, in those R-sensitive relapse,
Dara-Rd and Dara-Vd are the most potent options, followed by KRd, Ixa-Rd, VRd, Elo-Rd, pomalidomide combinations (PCd, KPd, VPd), or less
expensive regimens such as VCd, Vd or Kd (blue font). For patients who relapse on VRd induction, they are double V- and R-refractory, hence
managed as ‘intermediate’ relapse. However, if they relapse 2 years after VRd induction, they remain V- and R-sensitive; hence, both V- and
R-containing regimens will remain viable. Therefore, Dara-Rd and Dara-Vd are ﬁrst choices, followed by KRd, Ixa-Rd, Elo-Rd, in addition to
pomalidomide-containing regimens such as KPd, VPd, or to repeat VRd. In the ‘intermediate’ relapse category, who may be double V/R-
refractory, pomalidomide, daratumumab and carﬁlzomib-combinations are the main options in addition to single agent daratumumab. In
‘advanced’ relapse, clinical trials of agents with novel mechanism including exportin-1 inhibitor (selinexor combinations), or BCL2 inhibitor
(venetoclax combinations) in addition to immunotherapy (anti-BCMA CAR-T cells, allo-HSCT or anti-PD1 antibodies) have to be considered.
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such as PCd, KPd, VPd, or Pd, or to repeat VRd (Figures 2 and 3). In
the ‘intermediate’ relapse category, in which patients may be
double V/R-refractory, pomalidomide, daratumumab and
carﬁlzomib-combinations are the main options in addition to
single agent daratumumab. In ‘advanced’ relapse, clinical trials of
agents with novel mechanism including exportin-1 inhibitor
(selinexor combinations), or BCL2 inhibitor (venetoclax combina-
tions) in addition to immunotherapy (anti-B-cell maturation
antigen CAR-T cells, allo-HSCT or anti-PD1 antibodies) have to
be considered (Figures 2 and 3).
DISCUSSION
A few points are noteworthy. First, there is no head-to-head
comparison between next-generation novel agents. For instance,
there is no study to compare carﬁlzomib with ixazomib. Moreover,
while carﬁlzomib appears more potent than bortezomib in the
ENDEAVOR study in relapsing MM,19 the dose of carﬁlzomib was
56 mg/m2, instead of 27 mg/m2 used in the ASPIRE study for
RRMM.15
Secondly, among the novel agents discussed above, two agents
lack single agent activity, elotuzumab and panobinostat.72 As a
result, while daratumumab can be used as a single agent in
RRMM, elotuzumab has to be used in combination with
lenalidomie/dexamethasone. Moreover, while the clinical efﬁcacy
of bortezomib and panobinostat is a successful clinical translation
from the bench to bedside by which the aggresome pathway is
targeted, the role of panobinostat in RRMM is unclear because of
the availability of salvage agents that carry single agent activity in
MM including carﬁlzomib, ixazomib, pomalidomide, daratumu-
mab, venetoclax and selinexor, efﬁcacy of which was further
enhanced when combined with additional agents.
Thirdly, in this era of next-generation novel agents, the role of
salvage ASCT as a consolidation to prolong PFS and OS remains
important,66,67 hence still a standard in RRMM patients achieving a
response to next-generation novel agent combinations.
Finally, we need to address the enormous costs of the
combination of next-generation novel agents with immune
antibody-based therapies in order to assure access to these
therapies for patients worldwide.73
In summary, the efﬁcacy of next-generation PIs, IMiDs, and
monoclonal antibodies in patients with RRMM has been demon-
strated in RCTs. Optimal combination of these agents remains to be
deﬁned. Evaluation of these agents in frontline induction is underway,
which will hopefully result in deeper responses, as well as superior PFS
and OS of MM patients. With the advent of monoclonal antibodies, a
major breakthrough has been established in the treatment of MM.
The future of MM is promising as we use combinations of novel and
immune therapies earlier in the disease course.
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